米齐多胺数据显示CELMoD的潜力。
Mezigdomide Data Show CELMoD Potential.
出版信息
Cancer Discov. 2023 Nov 1;13(11):2300. doi: 10.1158/2159-8290.CD-NB2023-0065.
Abstract
The next-generation cereblon-targeting agent mezigdomide shows early signs of clinical efficacy in patients with heavily pretreated multiple myeloma, highlighting the potential of rational drug design to improve the potency of immunomodulatory therapies that function as molecular glues.
摘要
下一代靶向cereblon的药物米齐多胺在接受过大量治疗的多发性骨髓瘤患者中显示出早期临床疗效迹象，突出了合理药物设计在提高作为分子胶发挥作用的免疫调节疗法效力方面的潜力。
Zotero 插件